Upstate Active Clinical Trials
Study Title:
AALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyWhat is the purpose of the study? (in Layman's terms, please describe the study)
Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyUpstate Institutional Review Board (IRB) Number:
1521725Study/Protocol ID:
AALL1732Study Phase:
IIIPatient Age Group:
ChildrenPrincipal Investigator:
Melanie A ComitoWho is eligible?
Patients must be > 365 days and < 25 years of ageWhat is involved if I participate?
- How long is the study?
until accrual is met - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
blood draws, lumbar puncture, bone marrow biopsy/aspirate
Where will the study take place?
SUNY Upstate Medical UniversityOther Information:
N/AWho can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]